Interaction of IL-3 with its receptor is known to activate STAT-3 via phosphorylation of Tyrosine 701, which facilitates its dimerization and translocation to the nucleus, leading to the transcription of its target genes. In this communication, we have investigated the nature of tyrosine kinases that mediate STAT-3 phosphorylation during IL-3-mediated activation of myeloid cell proliferation. Our results show that interaction of IL-3 with its receptor leads to the activation of c-Src kinase activity, which in turn facilitates the binding of c-Src to STAT-3. This association leads to the phosphorylation of STAT-3, allowing this transcription factor to translocate to the nucleus. Expression of a dominant negative mutant of src (AMSrc) in these cells results in a block to IL-3 mediated phosphorylation of STAT-3, and its ability to bind to DNA. On the other hand, expression of a dominant negative mutant of JAK2 (JAK2KE) had no eect on IL-3-mediated activation of STAT-3. Our results also show that AMSrc does not aect the phosphorylation of JAK2, suggesting that JAK and STAT phosphorylation events are mediated by two independent pathways. Inhibition of c-Src activation by AMSrc, which leads to a block to STAT-3 activation, results in a dramatic inhibition of cell proliferation mediated by IL-3. However, expression of AMSrc does not activate apoptotic pathways. In contrast, expression of JAK2KE results in accelerated apoptosis of 32Dcl3 cells grown in the absence of IL-3 with concomitant down-regulation of Erk-2 kinase activity. These results suggest that Src family kinases mediate the phosphorylation of STATs and play a critical role in signal transduction pathways associated with myeloid cell proliferation while JAK kinases mediate the activation of Erk-2 pathway which appears to provide antiapoptotic signals. Thus the activation of JAKs and STATs appear to be two independent but related events, which dictate two separate biological outcomes, the combination of which results in proliferation and survival of myeloid precursor cells.
Introduction
Hematopoietic cell growth is mediated by a group of soluble growth factors, which bind to their cognate receptors and trigger the activation of latent cytoplasmic transcription factors termed STATs . These transcription factors were originally described by Darnell and his co-workers Darnell, 1996 Darnell, , 1997 as ligand-induced transcription factors in interferon-treated cells. Subsequent studies by a number of groups showed that STATs play a critical role in signal transduction pathways associated with several cytokines and neurokines including the interleukins, the interferons, erythropoietin, prolactin, growth hormone, oncostatin M (OSM), and ciliary neurotrophic factor (CNTF) (Eilers et al., 1994; Lehmann et al., 1994; Silva et al., 1996) . To date, seven mammalian genes that code for dierent STATs have been identi®ed, all of which encode for proteins of 750 ± 850 amino acids long and are characterized by the presence of a DNA-binding domain followed by putative SH3 and SH2 domains (Darnell, 1996) . These proteins, which are normally localized in the cytoplasm are activated when phosphorylated on a tyrosine located around residue 700, which facilitates their dimerization and translocation to the nucleus Schindler and Darnell, 1995) . The phosphorylation of STATs is known to occur immediately after the binding of growth factors or interferons to their receptors. Since this receptor-ligand interaction was also found to result in the activation of JAK kinases, which often exist in association with cytokine receptors, it was originally thought that STATs might be substrates for JAK kinases. However, accumulating evidence suggests that STAT activation may not be mediated by JAK kinases. Thus, the activated JAK kinases do not seem to exhibit speci®city for a particular STAT as dierent receptors activate a common STAT, even though they activate distinctively dierent JAK kinases (Kohlhuber et al., 1997; Darnell, 1997) . In addition, chimeric receptor molecules with dierent JAK binding sites but containing the same STAT-binding site were found to activate the same STAT (Kotenko et al., 1996; Kohlhuber et al., 1997) . Thus, the speci®city for STAT phosphorylation appears to be determined by the docking sites for STATs that are present in the receptor molecules and not JAK kinases (Stahl et al., 1995) . This leaves the question open as to which tyrosine kinases mediate the phosphorylation of STATs.
A clue to this question is provided by the observation that several oncogenes derived from the src family transform hematopoietic cells and render them cytokineindependent for growth (Pierce et al., 1985; Cook et al., 1985; Mathey-Prevot et al., 1986; Rovera et al., 1987) . Recent studies have provided conclusive evidence that these oncogenes bring about these transforming eects by constitutively activating STATs via tyrosine phosphorylation, often without activation of JAK kinases (Chaturvedi et al., 1997; Cao et al., 1996) , These observations suggest that normal cellular counterparts of these oncogenes might play a regulatory role in cytokine mediated activation of cell proliferation.
In this communication, we have investigated the nature of tyrosine kinases that mediate STAT phosphorylation during IL-3-mediated activation of myeloid cell proliferation. Our results show that interaction of IL-3 with its receptor leads to the activation of the c-Src kinase activity, which in turn faciliates the binding of c-Src to STAT-3. This association leads to the phosphorylation of STAT-3, which appears to be essential for IL-3-mediated cell proliferation.
Results

IL-3 stimulation of 32Dcl3 cells activates the kinase activity c-Src
To examine the mechanisms associated with IL-3 mediated activation of myeloid cell proliferation, we utilized the 32Dcl3 cell line, which is derived from normal mouse bone marrow and is non-tumorigenic Valtieri et al., 1987) . These cells are strictly dependent on IL-3 for survival and undergo apoptosis in the absence of this cytokine. To determine whether c-Src plays a role in IL-3 mediated signal transduction pathways, we examined the in vitro kinase activity of c-Src in immunoprecipitates derived from 32Dcl3 cells treated with IL-3 for various periods of time. For this, 32Dcl3 cells were ®rst cultured in the absence of IL-3 for 6 h and then stimulated with recombinant IL-3 for 10, 15, 30, 60 and 120 min. Following stimulation, cells were lysed and the lysates examined for the presence of endogenous c-Src by Western blotting technique. In addition, the same lysates were immunoprecipitated with monoclonal antibodies against c-Src and the precipitates subjected to in vitro kinase assays in the presence of an exogenous substrate, Enolase. Results of this experiment ( Figure 1) show that cells grown in the absence or presence of IL-3 contain equivalent level of endogenous c-Src. However, the c-Src protein immunoprecipitated from cells grown in the absence of IL-3 for 6 h did not exhibit any tyrosine kinase activity as measured by phosphorylation of Enolase or autophosphorylation of c-Src (lane 6, Figure 1 ). On the other hand, c-Src immunoprecipitates derived from IL-3 stimulated cells showed readily detectable in vitro kinase activity as measured by phosphorylation of Enolase as well as autophosphorylation of c-Src. Low levels of kinase activity was seen within 10 min following the addition of IL-3 to the cells (lane 1, Figure 1 ) and maximal levels of this kinase activity was seen in 30 min following the addition of IL-3 (lane 3, Figure 1 ). Our results also show that following the addition of IL-3, cSrc remains in a constitutively activated state as long as IL-3 was present in the growth medium. These results suggest that stimulation of 32Dcl3 cells with IL-3 leads to the activation of c-Src kinase activity. Since there is no apparent change in the endogenous levels of c-Src, it appears that this activation occurs exclusively throug post-translational modi®cations.
Activated c-Src in IL-3 stimulated cells associates with STAT-3
We next examined whether c-Src in IL-3-stimulated 32Dcl3 cells associates with STAT-3 and whether this association is dependent on its activated state. For this, 32Dcl3 cells were ®rst cultured in the absence of IL-3 for 6 h and then stimulated with recombinant IL-3 for 10 min to 2 h. The cell lysates were ®rst examined for the presence of c-Src and STAT-3 by Western blot analysis. Results from these experiments showed that both c-Src and STAT-3 were present in equivalent amounts in cells grown in the absence of IL-3 as well as in cells grown in the presence of IL-3 for various periods of time (Figure 2a and b) . We next immunoprecipitated these cell lysates with monoclonal antibodies against c-Src and resolved the immunoprecipitates on 10% SDS-polyacrylamide gels. The gels were then blotted onto a nytran paper and subjected to Western blot analysis using antibodies against STAT-3. Results of these experiments presented in Figure 2c show that c-Src immunoprecipitates derived from 32Dcl3 cells grown in the absence of IL-3 do not contain associated STAT-3 protein, even though these cells contain abundant amounts of both c-Src and STAT-3. On the other hand, c-Src immunoprecipitates derived from IL-3 stimulated cells exhibit association with STAT-3 within 10 min following the addition of IL-3 to the cells and the levels of associated STAT-3 reach a peak between 30 and 60 min following the addition of the cytokine. Since our earlier experiments show that c-Src-associated kinase activity reaches peak levels between 30 and 60 min, one could conclude that activation of c-Src is essential for its association with STAT-3. We could also demonstrate the interaction of c-Src with STAT-3 using polyclonal antibodies raised Figure 1 Activation of c-Src kinase activity by IL-3. Total cell lysates were prepared from 32Dcl3 cells maintained in 1 ng/ml of IL-3, 32Dcl3 cells which were depleted of IL-3 (7) for 6 h (H) and from cells where IL-3 was withdrawn for 6 h and then stimulated with 1 mg/ml of IL-3 (+) for various time points ranging from 10 min to 2 h. Equal amount of protein (150 mg) in each sample was immunoprecipitated (IP) with 5 ml of Src monoclonal antibody. The immunoprecipitates were washed thrice with lysis buer and once with kinase buer containing 20 mM HEPES pH 7.6, 20 mM MgCl 2 m 20 mM b-glycerophosphate, 20 mM P-nitrophenylphosphate, 0.1 mM Na 3 V0 4 and 2 mM DTT. Kinase reactions were performed with 20 mM rATP, 5 mCi of 32 P-gATP in 40 ml kinase buer for 20 min at 308C. Activated Enolase (10 mg/sample) (Boehringer ± Mannheim) was used an exogenous substrate. The samples were analysed by 12% SDS ± PAGE (top panel). For direct Western blot analysis, 80 mg of protein from each sample was resolved by 12% SDS ± PAGE, transferred to a nitrocellulose membrane and probed with anti-Src monoclonal antibody (bottom panel) against an N-terminal peptide of c-Src ( Figure 2D ). Results from this experiment again showed that STAT-3 co-immunoprecipitates with c-Src. The speci®city of c-Src binding to STAT-3 was indicated by the ability of the c-Src peptide against which the antiserum was raised to block immunoprecipitation of STAT-3 (Figure 2d ).
A dominant negative mutant of Src blocks IL-3 induced activation of To de®nitively demonstrate that c-Src mediates phosphorylation of STAT-3, we stably transfected 32Dcl3 cells with a tetracyline-repressible dominant negative mutant of Src (AMSrc) (Kaplan et al., 1994) . The ATP-binding site of this c-src mutant was inactivated by mutation of lysine 295 to arginine rendering this protein kinase-inactive. In addition, a phenylalanine substitution for tyrosine 527 prevents the intramolecular interaction between phosphorylated Y527 and the SH2 domain of this protein allowing the protein to exist in an open con®guration, thus making the SH2 and SH3 domains accessible to cellular binding proteins (Kaplan et al., 1994) . This protein was tagged with FLAG epitope at the Cterminal end, which allowed the detection of AMSrc independent of endogenous c-Src. Following electroporation of the expression vector into 32Dcl3 cells, the cells were selected with G418 and maintained in a medium containing 2 mg/ml of tetracyline, which blocked the expression of the mutant protein. To verify the inducible expression of AMSrc in 32D/ AMSrc cells, they were incubated in a medium lacking tetracycline for 24 h and the cell lysates subjected to Western blotting using anti-FLAG antibodies. As negative controls, cell lysates from parental 32Dcl3 cells and un-induced 32D/AMSrc cells were used. These Western blotting studies ( Figure 3a) showed that the AMSrc protein is not expressed in normal 32Dcl3 or 32D/AMSrc cells grown in the presence of tetracycline. However, high level expression of this protein could be induced in 32D/AMSrc cells upon the removal of tetracycline from the culture medium. We next examined whether the dominant negative form of Src binds to STAT-3, as was seen with c-Src and v-Src proteins (Yu et al., 1995; Cao et al., 1996; Chaturvedi et al., 1997) . Cell lysates prepared from 32D/v-Src and 32D/AMSrc cells were ®rst immunoprecipitated with anti-Src monoclonal antibody or anti-FLAG antibody and the immunoprecipitates resolved by SDS ± PAGE. The proteins were transferred onto a nytran membrane and the membrane probed with anti-STAT-3 antibodies. Results from this experiment ( Figure 3b ) showed that both v-Src and AMSrc bound equally well with STAT-3, suggesting that AMSrc retains the ability to interact with STAT-3, as was seen with other cellular substrates. To determine the phosphorylation status of STAT-3 in cells expressing AMSrc, total cell lysates from normal 32Dcl3 cells and 32D/ AMSrc cells growing in the presence of recombinant IL-3 were prepared. As positive controls, cell lysates from 32D/v-Src cells were used (Chaturvedi et al., 1997) . In this experiment, normal 32Dcl3 and 32D/ AMSrc cells were ®rst incubated for 6 h in a medium lacking of IL-3 and then stimulated with IL-3 for 10 min before lysis. The lysates were immunoprecipitated with anti-STAT-3 antibodies and the immunoprecipitates subjected to Western blotting. The Western blots were ®rst probed with anti-STAT-3 antibodies, which showed that all three cell lines expressed equivalent amounts of STAT-3 ( Figure 3c ). The Western blot was stripped and re-probed with 4G10 antibody which speci®cally recognizes the phosphotyrosine moiety. These studies revealed that this antibody readily recognizes STAT-3 present in normal 32Dcl3 cells growing in the presence of IL-3 and cells transfected with the v-src expression vector ( Figure 3c ). However, this antibody failed to recognize STAT-3 in cell lysates derived from 32Dcl3/AMSrc cells cultures in the presence of Il-3. These results show that phosphorylation of STAT-3 following IL-3 stimulation of 32Dcl3 cells is blocked by AMSrc indicating that STAT-3 is a substrate of cSrc. Normal 32Dcl3 cells maintained in the presence of IL-3 were depleted of IL-3 for 6 h and then stimulated with IL-3 for de®ned periods of time ranging from 10 min to 2 h. Total cell lysates from each sample were prepared and resolved on 10% SDSpolyacrylamide gels and immunoblotted with (a) anti-Src monoclonal antibody of (b) with anti-STAT-3 antibody. (c) The cell lysates were immunoprecipitated (IP) with anti-Src monoclonal antibody or with preimmune serum (PI) and the resulting immune complexes were resolved by 10% SDS ± PAGE and immunoblotted with anti-STAT3 antibody. (d) Total cell lysate prepared from 32Dcl3 were immunoprecipitated with anti-Src (N-16) antibody or with antibody preincubated with ten times excess of Src peptide for 2 h at 48C. The immune-complexes were then resolved on 10% SDS-polyacrylamide gels and immunoblotted using anti-STAT-3 antibody Dominant negative Src interferes with the DNA binding activity of To determine whether AMSrc interferes with the DNA-binding activity of STAT-3, we next examined the DNA-binding ability of STAT-3 present in 32Dcl3 and 32D/AMSrc cells. These assays were performed with the acute phase response element (APRE) highanity Sis-inducible element (SIE), which was previously shown to bind to STAT-3 with high anity (Zhong et al., 1994) . These studies showed (Figure 4 ) that nuclear extracts derived from normal 32Dcl3 cells stimulated with IL-3 gave a single shifted band. In addition, a mutant oligonucleotide with point mutations in the binding sequence failed to form such a complex. On the other hand, when these gel shift assays were performed with nuclear extracts derived from 32D/AMSrc cells, stimulated with IL-3, we failed to detect signi®cant amounts of a shifted band suggesting that dominant negative Src interferes with the DNA binding activity of STAT-3, presumably by blocking its phosphorylation on tyrosine.
Eect of dominant negative Src on activation of JAK kinases
It has been previously shown that interaction of IL-3 with its receptor results in activation JAK2 kinase through an event associated with tyrosine phosphorylation (Silvennoinen et al., 1993) . It is possible that cSrc mediates phosphorylation of STAT-3 by activation of JAK2 kinase. To determine the status of JAK2 kinase in 32D/AMSrc cells we examined the levels of JAK2 protein as well as its phosphorylation status in these cells and compared it with normal cells. We immunoprecipitated cell extracts from normal 32D and 32D/AMSrc cells with JAK2-speci®c antibody and Western blotted with JAK2 antibody and with monoclonal antibody 4G10. Immunoprecipitates from 32Dcl3 cells stimulated with IL-3 were used as a positive control. 32D/v-Src cells were used as a negative control. These cells grow in the absence of were fractionated on 12% SDS-polyacrylamide gels and the resolved proteins were immunoblotted with anti-FLAG antibodies (b) Total cell lysates were prepared from 32D/v-Src and 32D/ AMSrc cells grown in the absence of tetracyclin and 1 mg protein from each sample was immunoprecipitated with anti-FLAG antibody or anti-Src monoclonal antibody or with preimmune serum (PI) for 2 h at 48C. The immune-complexes were separated on 10% SDS-polyacrylamide gels, blotted and then probed with anti-STAT-3 antibody. (c) Normal 32Dcl3 and 32D/AMSrc cells growing in the presence of recombinant IL-3 were depleted of IL-3 for 6 h and then stimualted with IL-3 for 10 min. Total cell lysates were prepared from these cells as well as 32D/v-Src cells growing in the absence of IL-3 and the lysates were immunoprecipitated with anti-STAT-3 antibodies. The blots were ®rst probed with anti-STAT-3 antibody. They were next stripped and re-probed with 4G10 antibody Figure 4 DNA-binding activity of STAT-3 in 32Dcl3 and 32D/ AMSrc cells. Nuclear extracts were prepared from normal 32Dcl3 cells and 32D/AMSrc cells that were starved for IL-3 for 6 h and then induced with IL-3 for 10 min. Nuclear extracts containing 7 mg of protein were used to carry out EMSA with 10 000 c.p.m. of 32 P-labeled STAT-3 speci®c and mutant oligonucleotides as described in Materials and methods. A mutant oligonucleotide (indicated by an asterisk) where the binding sequence was altered was used as a negative control IL-3-Induced activation of STAT3 is mediated by c-Src P Chaturvedi et al IL-3 and were previously shown not to contain the activated form of JAK2 (Chaturvedi et al., 1997) . The results from this experiment show that JAK2 is both present (Figure 5a ) and is phosphorylated (Figure 5b ) in both normal 32Dcl3 and 32D/AMSrc cells grown in the presence of IL-3 while it is not phosphorylated in 32D/v-Src cells (which are grown in the absence of IL-3). These results allow us to conclude that IL-3 activates JAK2 phosphorylation and this event does not require the activation of c-Src kinase activity. In addition, these results demonstrate that the presence of activated JAK2 is not adequate to achieve the phosphorylation of STAT-3.
Eect of dominant negative Src (AMSrc) on IL-3 induced proliferation
To investigate the eect of AMSrc on 32D cell proliferation, we analysed the growth pattern of 32D/ AMSrc cells and compared it with normal 32Dcl3 cells. Normal 32Dcl3 cells and 32D/AMSrc cells were maintained in IMDM, supplemented with 10% FBS and 10% WEHI-3B conditioned medium as a source of IL-3. The cells were plated at a density of 1610 5 cells/ ml and cell viability and density determined at 24 h intervals for 7 days (Figure 6 ). In the presence of IL-3, normal 32Dcl3 cells doubled approximately every 24 h and grew in a logarithmic manner and had to be split every 72 h to allow maximal growth. The growth rate of 32 /AMSrc cells was similar to that of normal 32Dcl3 cells, when these cells were grown in the presence of IL-3 and tetracycline (which represses the expression of dominant negative Src). However, when AMSrc protein synthesis was induced by removing tetracyline from the growth medium, their proliferation rate was drastically reduced and the cells doubled approximately every 96 h. When we examined their viability following trypan blue staining, they were found to be 490% viable. These results suggest that AMSrc expression in 32Dcl3 cells results in severely reduced proliferation of myeloid cells in the presence of IL-3 and this could be attributed to the absence of an activated form of STAT-3.
Eect of a dominant negative mutant of JAK2 (JAK2KE) on proliferation and apoptosis of 32Dcl3 cells
To investigate the role of JAK-2 in IL-3-induced proliferation of 32Dcl3 cells, we stably transfected these cells with a kinase-negative mutant of JAK2 (JAK2KE), which has been previously shown to act in a dominant negative manner (Briscoe et al., 1995; Kohlhuber et al., 1997) . Thus mutant was made by replacing the highly conserved lysine (K) in motif II of the tyrosine kinae domain with glutamic acid (E). To distinguish this mutant protein from endogenous JAK2, we tagged this protein with the FLAG epitope. Individual clones (32D/JAK2KE) expressing high levels of this protein were selected and were veri®ed for the expression of the mutant protein using antibodies speci®c to the FLAG epitope. For this, cell lysates were prepared from normal 32Dcl3 and 32D/ JAK2KE cells and subjected to Western blotting with anti-FLAG antibody which showed that JAK2KE is expressed at high levels in 32D/JAK2KE cells, while this protein is not seen in normal 32Dcl3 cells ( Figure  7a ).
We next studied the eect of JAK2KE expression on IL-3-mediated activation of STAT-3. To determine the phosphorylation status of STAT-3 in cells expressing JAK2KE, total cell lysates from normal 32Dcl3 cells and 32D/JAK2KE cells growing in the presence of recombinant IL-3 were prepared. Cell lysates from 32D/AMSrc cells were included as a negative control for STAT-3 phosphorylation. Cells were ®rst incubated for 6 h in a medium lacking IL-3 and then stimulated with IL-3 for 10 min before lysis. The lysates were subjected to Western blotting. The blots were probed with anti-STAT-3 antibody, as well as with antiphospho-STAT-3 antibody which speci®cally recognizes the phosphotyrosine moiety of STAT-3. These studies revealed that STAT-3 is present in normal 32Dcl3 as well as 32D/JAK2KE and 32D/AMSrc cells growing in the presence of IL-3 (Figure 7b ). However, unlike with AMSrc, IL-3-mediated phosphorylation of Figure 5 JAK activation in 32D cells expressing dominant negative Src. Normal 32Dcl3 cells and 32D/AMSrc cells (grown in the absence of tetracyclin) were depleted of IL-3 for 6 h and then stimulated with IL-3 for 10 min. Whole cell lysates from the indicated cells containing equal amounts of protein were immunoprecipitated with 5 ml each of anti-JAK2 antibody and subjected to 8% SDS ± PAGE. Western blot analysis was then performed with anti-JAK2 antibody (a). The blot was then stripped and reprobed with 4G10 anti-phosphotyrosine monoclonal antibody (b) Figure 6 Inhibition of IL-3-mediated cell proliferation by AMSrc. Normal 32Dcl3 cells were maintained in IMDM medium supplemented with 10% FBS and 10% WEHI-3B conditioned medium as a source of IL-3, 32D/AMSrc cells were maintained in the same medium but in the presence (32DAMSrc) or absence of tetracyclin (32DAMSrc*) to repress or induce the expression of AMSrc as described in Materials and methods. The cells were plated at a density of 1610 5 cells/ml and the cell number and viability were determined at 24 h intervals for 7 days IL-3-Induced activation of STAT3 is mediated by c-Src P Chaturvedi et al STAT-3 is unaected by the expression of the dominant negative mutant of JAK2 (JAK2KE).
To investigate the eect of JAK2KE on 32D cell proliferation, we analysed the growth pattern of 32D/ JAK2KE cells. Normal 32Dcl3 cells and 32D/JAK2KE cells were maintained in IMDM, supplemented with 10% FBS and 10% WEHI-3B conditioned medium as a source of IL-3. The cells were plated at a density of 1610 5 cells/ml and cell viability and density determined at 24 h intervals for 6 days (Figure 7c ). In the presence of IL-3, both normal 32Dcl3 and 32D/ JAK2KE cells doubled approximately every 24 h and grew in a logarithmic manner. When we examined their viability following trypan blue staining, both cultures were found to be 490% viable. These results suggest that unlike with AMSrc, expression of JAK2KE in 32Dcl3 cells does not aect their ability to proliferate in the presence of IL-3.
Next, we studied the eects of AMSrc and JAK2KE on 32 D cell apoptosis induced by the removal of IL-3. For this, exponentially growing normal 32Dcl3, 32D/ AMSrc and 32D/JAK2KE cells were depleted of IL-3 by washing the cells thoroughly with phosphatebuered saline (PBS). The washed cells were then replated at 2610 5 cells/ml density in IMDM medium devoid of IL-3 and were analysed for viability for 24 h. Results presented in Figure 7d indicate that the expression of JAK2KE mutant in 32Dcl3 cells accelerates its apoptotic rate induced by the withdrawal of IL-3, while similar expression of AMSrc does not. Thus, 53% of the normal 32Dcl cells and 55% of AMSrc were viable after 14 h of IL-3 withdrawal, while only 14.8% of 32D/JAK2KE cells were viable at this time point, indicating that JAK2KE transfected 32D cells apoptose much faster than the normal 32Dcl3 or 32D/AMSrc cells.
JAK2KE eects are manifested via the ERK-2 pathway
The role of activation of ERK and JNK in growth factor mediated proliferation and survival is now well established. The activation of JNK and inhibition of ERK kinase activity have been shown to be critical for induction of apoptosis in PC-12 cells (Xia et al., 1995) . In 32Dcl3 cells, expression of JAK2KE confers accelerated apoptotic rate upon withdrawal of IL-3, suggesting a role for the JAK2 pathway in antiapoptotic signaling mechanisms. To determine whether the expression of JAK2KE aects the ERK-2 and JNK pathways, we examined the kinase activities of ERK-2 and JNK in the presence and absence of IL-3 in normal 32Dcl3 cells and in 32D/JAK2KE cells. Cell lysates from normal 32Dcl3 and 32D/JAK2KE cells were prepared from cells growing in the presence of IL-3 and from cells incubated in the absence of IL-3 for 2 ± 16 h and the lysates immunoprecipitated with antibodies speci®c for ERK-2 or JNK. The ERK-2 immunoprecipitates were assayed for kinase activity using myelin basic protein (MBP) as a substrate. Similarly, the JNK immunoprecipitates were assayed for their ability to phosphorylate GST-JUN. Results presented in Figure 8 show that expression of JAK2KE mutant in 32Dcl3 cells does not aect the ERK-2 kinase activity in the presence of IL-3. However its expression was found to drastically inhibit ERK-2 kinase activity in 32Dcl3 cells grown in the absence of IL-3. Strong inhibition of ERK-2 activity (460%) was seen within 2 h following IL-3 withdrawal, which continued for the next several hours until the kinase activity became undetectable. Our results also show that expression of JAK2KE had no eect on JNK activity as well as PI3 kinase and AKT activities of 32D cells grown in the presence or absence of IL-3 (data not shown). These results suggest that JAK2 pathway is associated with the activation of ERK-2 kinase activity, which in turn provides an antiapoptotic signal. The acceleration of apoptosis seen in 32D/JAK2KE cells following the withdrawal of IL-3 could be due to down-regulation of ERK-2 activity in these cells.
Discussion
In this communication, we provide evidence for a critical role played by c-Src in cytokine-mediated cell proliferation and delineate the signal transduction pathways by which this tyrosine kinase mediates these eects. A large number of cytokines, neurokines and interferons have been recently shown to interact with their receptors and trigger the activation of proliferative and dierentiation pathways in these cells (Kishimoto et al., 1994; Ihle, 1995; Sachs and Lotem, 1994) . Current models suggest that interaction of a cytokine with its receptor induces receptor dimerization which increases the anity of the cytoplasmic domain of the receptor for JAK kinases (Leaman et al., 1996; Ihle, 1995) . This results in a ligand-dependent increase of a complex that contains the receptors and JAK kinases which have been activated through an event associated with tyrosine phosphorylation. The activated JAK kinases appear to subsequently phosphorylate the C-terminal end of receptors that serve as the docking sites for STATs. The receptor bound STAT is then phosphorylated on tyrosine, which in turn leads to its activation (Schindler and Darnell, 1995; Leaman et al., 1996; Ihle and Kerr, 1995; Kohlburger et al., 1997) .
STATs, originally described as mediators of interferon-action, have a unique structure and represent a multi-gene family which plays a central role in many dierent signal transduction pathways Darnell, 1997) . To date, seven dierent STAT genes have been identi®ed, several of which seem to code for multiple proteins due to alternative splicing of the encoded mRNAs (Darnell, 1997) . All the seven STATs described so far are approximately 750 ± 850 amino acids long and have a modular structure with a distinctive DNA-binding domain, a putative SH3 domain and an SH2 domain (Darnell, 1997) . In the absence of cytokine stimulation, these proteins are localized in the cytoplasm but become tyrosine phosphorylated on tyrosine within minutes following cytokine/interferon stimulation of cells (Schindler and Darnell, 1995; Ihle, 1995) .
To investigate the mechanisms associated with STAT-3 phosphorylation, we used an IL-3-dependent cell line, 32Dcl3, which is derived from normal mouse bone marrow and is strictly dependent on IL-3 for growth . This cell line, which is non-tumorigenic can be made to dierentiate into granulocytes by the addition of G-CSF to the culture medium and has been found to rapidly undergo apoptosis, when cultured in the absence of cytokines (Nunez et al., 1990; Gaozza et al., 1997) . Results presented in this study show that addition of IL-3 to the culture medium results in the immediate activation of c-Src kinase activity as measured by its ability to phosphorylate itself and phosphorylate an exogenous substrate, Enolase. Activation of this kinase activity appears to result in an ability of c-Src to bind to STAT-3 and phosphorylate STAT-3. We believe that this interaction is made possible by the acquisition of an open con®guration by activated c-Src, which allows the SH2 and SH3 domains of the protein to interact with cellular substrates. This notion if further supported by the fact that the dominant negative mutant form of c-Src, which is kinase-inactive but contains a Tyr to Phe mutation at position 527 can bind STAT-3 as well as kinase-active c-Src. It therefore appears that an open conformation of c-Src, rather than its kinase activity is important for this interaction. Similarly v-Src, which has a C-terminal deletion that Figure 8 Inhibition of ERK-2 kinase activity by JAK2KE. Whole cell lysates were prepared from normal 32Dcl3 cells and those transfected with JAK2KE expression vector. Cells actively growing in the presence of IL-3 or induced to undergo apoptosis in the absence of IL-3 for 30 min and 2 h were used for these assays. Each lysate containing equal amount of protein (100 mg) was immunoprecipitated with anti-ERK-2 antibody and used for determining the kinase activity using the Myelin Basic Protein (MBP) as an exogenous substrate. The assay samples were analysed by 15% SDS ± PAGE allows this protein to remain in an open conformation binds to STAT-3 with high avidity (Chaturvedi et al., 1997; Cao et al., 1996) . >Our results with the dominant negative mutant of Src provide strong evidence that STAT-3, in normal cells is indeed activated by c-Src. In 32D/AMSrc cells, IL-3 fails to induce the activation of STAT-3, which in turn results in the inability of STAT-3 to bind to DNA. Furthermore, addition of IL-3 to 32D/AMSrc cells leads to the activation of JAK-2 as judged by its phosphorylation on tyrosine, which however does not seem to be adequate to phosphorylate STAT-3. These results suggest that the pathways associated with the activation of JAKs and STATs are distinctive. This is further con®rmed by our analysis of 32Dcl3 cells expressing the dominant negative form of JAK2 (JAK2KE), which does not seem to aect the activation of STAT-3. In addition, expression of AMSrc and JAK2KE appear to produce two biologically dierent phenotypes in 32Dcl3. Thus, the expression of AMSrc was seen to result in an inhibition of the ability of these cells to proliferate in response to IL-3, while the expression of JAK2KE had no eect on IL-3-induced cell proliferation. However, expression of JAK2KE appeared to accelerate the rate of apoptosis, when 32Dcl3 cells were cultured in the absence of IL-3, while AMSrc did not accelerate apoptotic death of these cells. Expression of JAK2KE was also found to result in an inhibition of ERK-2 kinase activity in cells grown in the absence of IL-3, suggesting that the JAK2 pathway might function via ERK-2. It has recently been shown that JAK kinases are phosphorylated on multiple tyrosines following stimulation by cytokines, which in turn, serve as docking sites for other signal transducing proteins such as CIS, JAB, SHC (Endo et al., 1997; Giordano et al., 1997; Watanabe et al., 1996 Watanabe et al., , 1997 Yoshimura et al., 1995) . It is possible that ERK-2 is directly activated by JAK2 or some of the adapter proteins play a critical role in linking the JAK2 kinase activity with the activation of ERK-2 thus playing a critical role in mediating the anti-apoptotic eects of IL-3.
In conclusion, our results strongly suggest that IL-3 mediated activation of JAKs and STATs are two independent but related events, and these two events dictate two separate biological outcomes, the combination of which results in proliferation and survival of myeloid precursor cells. Our results also demonstrate that the STAT-3 pathway mediates the proliferative events while the JAK pathway mediates the antiapoptotic and possibly other biological eects of IL-3. Additional studies aimed at understanding the nature of genes activated by STAT and JAK pathways will undoubtedly lead to a better understanding of the mechanisms by which interleukins, neurokines and interferons bring about their divergent biological eects.
Materials and methods
Cells, antibodies and reagents
The murine hematopoietic cell line 32Dcl3 was maintained in Iscoves modi®ed Dulbecco medium (IMDM), supplemented with 10% fetal bovine serum (FBS) (complete medium) and 1 ng/ml of recombinant IL-3 in a 378C incubator with 5% CO 2 . The v-src transformed 32D cells (32D/v-Src) were maintained in the same medium but lacking IL-3. The Src dominant negative mutant containing 32D cell line (32D/AMSrc) was generated by transfection of Src mutant cDNA (Kaplan et al., 1994) in a tetracycline inducible vector (O'Brien et al., 1997) with the FLAG epitope at its 3' end along with PMV-7 vector containing Neomycin resistance gene. Following electroporation, positive clones were selected for G418 resistance and tested for AMSrc expression by western blotting technique using the anti-FLAG antibody. These cells were maintained in complete medium containing 10% IL-3 and 2 mg/ ml of tetracycline. The AMSrc protein was induced by culturing cells in the absence of tetracycline for 24 ± 48 h. The JAK2 dominant negative mutant expressing 32D cell line (32D/JAK2KE) was generated by transfection of JAK2KE cDNA (Briscoe et al., 1995; Kohlhuber et al., 1997) in pFLAG-CMV-2 vector (Kodak Scienti®c Imaging). PMV-7 vector containing Neomycin resistance gene was cotransfected along with it.
The FLAG antibody (D-8), the anti-PI3 kinase antibody (Z-8), the STAT-3 (C-20) antibody and the anti-Src antibody (N-16) were purchased from Santa Cruz Biotechnologies. The monoclonal anti-Src antibody (05-184), the anti-JAK 2 antibody and the 4G10 anti-phosphotyrosine antibody were purchased from Upstate Biotechnologies. The anti-phosphospeci®c-STAT-3 antibody was purchased from New England Biolabs. Rabbit anti-mouse antibody (secondary antibody for anti-STAT-3) and mouse monoclonal antibody (secondary antibody for anti-Phosphotyrosine and Src) were purchased from Amersham. Protein A-Sepharose was purchased from Life Technologies.
Tyrosine kinase assay
For kinase assays, cells were collected at each time point, centrifuged and lysed in lysis buer containing 25 mM HEPES pH 7.6, 0.1% Triton-X100, 300 mM NaCl, 20 mM b-glycerophosphate, 1.5 mM MgCl 2 , 0.2 mM EDTA, 2.0 mM DTT, 0.2 mM Na 3 VO 4 , 2 mg/ml leupeptin and 4 mg/ml aprotinin for 30 min at 48C. Each lysate containing equal amount of protein (150 mg) was immunoprecipitated (IP) with respective antibody at 48C for 2 h followed by incubation with protein A sepharose for 45 min at 48C. The immunoprecipitates were washed thrice with lysis buer and once with kinase buer containing 20 mM HEPES pH 7.6, 20 mM MgCl 2 , 20 mM b-glycerophosphate, 20 mM p-nitrophenylphosphate, 0.1 mM Na 3 V0 4 and 2 mM DTT. Kinase reactions were performed with 20 mM rATP, 5 mCi of 32 P-gATP in 40 ml kinase buer for 20 min at 308C in the presence of Enolase or the Myelin Basic Protein (MBP) (Chaturvedi et al., 1997; Hibi et al., 1993) . The samples were analysed using SDS ± polyacrylamide gels. Following electrophoresis, the gels were dried and subjected to autoradiography.
Western blotting
For the detection of STAT-3, c-Src, AMSrc and JAK2KE proteins, Western blotting assay was performed. The cells were lysed in a buer containing 1% NP40 in PBS, 1 mM PMSF, 4 mg/ml aprotinin, 4 mg/ml pepstatin A and 4 mg/ml leupeptin. Equivalent amounts of cell lysates (80 mg) were subjected to SDS ± PAGE and the resolved proteins were transferred to Nytran membranes. The membranes were blocked in 5% milk for 30 min at room temperature and then incubated with the primary antibody (anti-STAT-3 antibody or anti-FLAG antibody or anti-Src antibody, N-16) for 1 h at room temperature with constant agitation. The ®lters were then washed thrice with T-TBST (0.05% Tween-20, 20 mM Tris pH 7.5, 150 mM NaCl) and incubated with secondary antibody (goat anti-rabbit IgG linked to horse radish peroxidase) (1 : 10 000 dilution) for 30 min at room temperature. The reacted bands were detected with enhanced chemiluminescence (ECL, Amersham). For JAK antibodies, antiphosphotyrosine antibody (4G10) and Src monoclonal antibody we followed the manufacturer's instructions for blocking and antibody incubation conditions.
Immunoprecipitation
For STAT and JAK kinase phosphorylation assay, normal 32Dcl3 cells and 32D/AMSrc cells, maintained in 1 ng/ml recombinant IL-3 were depleted of IL-3 for 6 h and then stimulated with 1 mg/ml of IL-3 for 10 min. 5610 6 cells/ sample were lysed for each immunoprecipitation. For STAT phosphorylation assay the cells were lysed in a buer containing 1% NP40, 1 mM PMSF, 4 mg/ml of aprotinin, 4 mg/ml of pepstatin A and 4 mg/ml of leupeptin in PBS for 30 min at 48C. For JAK immunoprecipitation, cells were lysed in a buer containing 25 mM HEPES pH 7.6, 0.1% Triton-X100, 300 mM NaCl, 20 mM b-glycerophosphate, 1.5 mM MgCl 2 0.2 mM EDTA, 2.0 mM DTT, 0.2 mM Na 3 VO 4 , 2 mg/ml leupeptin and 4 mg/ml aprotinin. The total cell lysate was immunoprecipitated with anti-STAT3 or JAK speci®c antibody for 2 h at 48C followed by incubation with protein A sepharose for 1 h at 48C. The immunoprecipitates were then collected by centrifugation, washed thrice with the lysis buer, dissolved by boiling in Laemmli buer (Laemmli, 1970) and subjected to SDS ± PAGE. For v-Src and STAT co-immunoprecipitation assay, lysis buer was the same as for STAT immunoprecipitations. Equal amount of protein (1 mg) in each sample was immunoprecipitated with anti-Src monoclonal antibody (UBI) for 2 h at 48C. The immunoprecipitate was then incubated with Protein A Sepharose for 1 h at 48C and then collected by centrifugation, washed and subjected to SDS ± PAGE.
To perform the assay for peptide neutralization of the immune complex, exponentially growing cells were harvested, pelleted and lysed in the same lysis buer as mentioned above. Equal amounts of protein (1 mg) was used for immunoprecipitation with anti-Src (N-16) antibody (0.005 mg). Total cell lysates were incubated with anti-Src antibody for 2 h at 48C or with antibody preincubated with ten times excess of Src peptide (for 2 h at room temperature) followed by incubation with protein A sepharose for 1 h at 48C. The immune-complex was then separated on a 10% SDS-polyacrylamide gel and Western blot analysis was performed.
Electrophoretic mobility shift assay
Nuclear extracts from 32Dcl3 and 32D/AMSrc cells were prepared using the protocol described by Schrieber et al. (1989) . Cells growing in the presence of IL-3 were depleted of IL-3 for 6 h and then stimulated with IL-3 for 10 min. STAT-3 speci®c oligonucleotides and their mutant counterpart were purchased from Santa Cruz Biotechnology. The binding sequence for STAT-3 was described by Yu et al. (1995) . The sequence of the probes used in the assays is: STAT-3:
5'-GATCCTTCTGGAATTCCTAGATC-3' STAT-3*(mutant):
5'-GATCCTTCTGGGC*C*G*TCCTAGATC-3'
For STAT-3 mobility shift assays, 7 mg of nuclear extract was incubated with 1 ng of 32 P-labeled probe or with the mutant oligonucleotide in 10 ml of binding buer (50 mM Tris pH 7.5, 5 mM MgCl 2 , 250 mM NaCl, 5 mM EDTA, 2.5 mM dithiothritol (DTT), 20% glycerine, 50 mg/ml Single Standard DNA, 0.25 mg/ml PolydI.dC) for 30 min at room temperature and electrophoresed on non-denaturing 5% polyacrylamide gels in 0.5% TBE buer (25 mM Tris, 25 mM Boric acid and 10 mM EDTA) as described by Schrieber et al. (1989) . One mg of poly(dI-dC) was used as nonspeci®c DNA competitor in each reaction. The probe was prepared by end labeling the double-stranded oligonucleotide with [ 32 P]gATP using T4 nucleotide kinase.
